Severe haemophilia A with haemarthrosis improved on emicizumab: A case report

Abstract

Severe haemophilia A is associated with serious spontaneous bleeding in muscles, soft tissues, and joints. Haemarthrosis, bleeding into joints, is a serious complication of haemophilia. Emicizumab is a novel non-factor replacement agent for preventing or reducing the frequency of bleeding episodes in adults and children with haemophilia A with or without inhibitors.

Keywords

• emicizumab
• haemophilia a
• bleeding
• quality of life
• case report